Pharmaceutical Industry News
Glenmark Pharma introduces 400 mg version of FabiFlu for COVID-19 treatment
Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, announced that it will introduce a 400 mg version of oral antiviral FabiFlu, for the treatment of mild to moderate COVID-19 in India. The higher strength will improve patient compliance and experience, by effectively reducing the number of tablets that patients
Manufacturing | 06/08/2020 | By Darshana
Lupin gets US FDA approval for generic Glyxambi tablets
Pharma major Lupin Limited has received tentative approval for its empagliflozin and linagliptin tablets, 10 mg/5 mg and 25 mg/5 mg, from the United States Food and Drug Administration (FDA) to market a generic version of Glyxambi tablets, 10 mg/5 mg and 25 mg/5 mg, of Boehringer Ingelheim Pharmaceuticals, Inc
Manufacturing | 24/07/2020 | By Darshana
The 80-year old Indian Pharmaceutical Association (IPA), the national professional body of pharmacists engaged in various facets of the profession of pharmacy, will soon approach the national Trade Marks Registry (TMR) for the exclusive right of its acronym, IPA. A decision to approach the TMR, claiming absolute ownership of the acronym
Manufacturing | 22/07/2020 | By Darshana
Patanjali launches ayurvedic medicine Coronil and Swasari to treat COVID-19
Baba Ramdev?s Patanjali Yogapeeth based in Haridwar has launched ayurvedic medicine 'Coronil and Swasari', to treat the noval coronavirus infection (COVID-19), which the company said has been shown 100 per cent favourable results during clinical trials on affected patients
Manufacturing | 23/06/2020 | By Darshana
FDA Publicly Shares Antibody Test Performance Data From Kits as Part of Validation Study
Today, the U.S. Food and Drug Administration publicly posted test performance data from four more antibody, or serology, test kits on open.fda.gov from its independent performance validation study effort with the National Institutes of Health?s (NIH) National Cancer Institute (NCI)
Manufacturing | 05/06/2020 | By Darshana
FDA Approves Only Drug in U.S. to Treat Severe Malaria
Today, the U.S. Food and Drug Administration approved artesunate for injection to treat severe malaria in adult and pediatric patients. Treatment of severe malaria with intravenous (IV) artesunate should always be followed by a complete treatment course of an appropriate oral antimalarial regimen
Manufacturing | 27/05/2020 | By Darshana | 171
The department of Ayurveda, Yoga, Unani, Shiddha and Homoeopathy (Ayush) in collaboration with Council of Scientific and Industrial Research (CSIR) is working on developing four formulations of traditional medicine to treat the novel coronavirus infections and accordingly clinical trials are also being planned within next one week
Manufacturing | 19/05/2020 | By Darshana
Cipla Limited has signed a non-exclusive licensing agreement with Gilead Sciences, Inc. for the manufacturing and distribution of the investigational medicine remdesivir, which has been issued an Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) to treat COVID-19 patients
Manufacturing | 13/05/2020 | By Darshana
Abbott announces CE mark approval for its COVID-19 laboratory based antibody test in India
Abbott announced that it received CE Mark to the IVD Directive (98/79/EC) for its laboratory-based serology blood test for the detection of the antibody, IgG, that identifies if a person has had the novel coronavirus (COVID-19)
Manufacturing | 05/05/2020 | By Darshana | 106
Roche's COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets
Roche has already started shipping the new antibody test to leading laboratories globally and will ramp up production capacity to high double-digit millions per month to serve healthcare systems in countries accepting the CE mark2 as well as the U.S.<br />
Manufacturing | 04/05/2020 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy